Geng Jiawei, Chen Xuejie, Wang Sidan, Dan Lintao, Gong Qijia, Chen Jie, Wang Xiaoyan, Cao Xiaocang, Du Zhongyan
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Centre for Global Health, Zhejiang University, Hangzhou, China.
Eur J Nutr. 2025 May 28;64(5):191. doi: 10.1007/s00394-025-03705-x.
We aim to evaluate the association between the use of glucosamine, a widely used dietary supplement, and the risk of IBD-related surgery in a prospective cohort study.
We leveraged data from 6059 individuals with IBD from the UK Biobank. Habitual use, frequency of use, and the dose of glucosamine were evaluated using self-reported records, multiple rounds of dietary recall, and prescription information from primary care data, respectively. IBD-related surgery was identified through inpatient data. Cox proportional-hazard model and logistic regression model were applied to examine the associations.
During a mean follow-up of 12.2 years, we documented 684 incident IBD-related surgery events. Compared with non-users, habitual glucosamine users presented (66.6 vs 97.1 cases/10,000 person-years, HR 0.73, 95% CI 0.58-0.92, P = 0.009) lowered risk of IBD-related surgery, decreased risk in Crohn's disease (80.6 vs 131.0 cases/10,000 person-years, HR 0.60, 95% CI 0.41-0.89, P = 0.011), while it was not significant in ulcerative colitis (61.1 vs 79.5 cases/10,000 person-years, HR 0.88, 95% CI 0.65-1.18, P = 0.386). The risks of IBD-related surgery were also lower among occasional users (HR 0.34, 95% CI 0.15-0.77, P = 0.010) and constant users (HR 0.48, 95% CI 0.25-0.90, P = 0.022) than non-users. For those using prescribed glucosamine, a higher prescription dose was associated with a lower risk of related surgery (OR 0.15, 95% CI 0.02-0.86, P = 0.034).
Use of glucosamine, as a safe dietary supplement, is associated with a lower risk of IBD-related surgery, which would be a promising strategy in IBD management.
我们旨在通过一项前瞻性队列研究，评估广泛使用的膳食补充剂氨基葡萄糖的使用与炎症性肠病（IBD）相关手术风险之间的关联。
我们利用了英国生物银行中6059名IBD患者的数据。分别使用自我报告记录、多轮饮食回忆以及基层医疗数据中的处方信息，评估氨基葡萄糖的习惯性使用情况、使用频率和剂量。通过住院患者数据确定IBD相关手术。应用Cox比例风险模型和逻辑回归模型来检验这些关联。
在平均12.2年的随访期间，我们记录了684例IBD相关手术事件。与未使用者相比，习惯性使用氨基葡萄糖的患者（每10000人年66.6例对97.1例，风险比[HR]0.73，95%置信区间[CI]0.58 - 0.92，P = 0.009）IBD相关手术风险降低，克罗恩病风险降低（每10000人年80.6例对131.0例，HR 0.60，95% CI 0.41 - 0.89，P = 0.011），而在溃疡性结肠炎中不显著（每10000人年61.1例对79.5例，HR 0.88，95% CI 0.65 - 1.18，P = 0.386）。偶尔使用者（HR 0.34，95% CI 0.15 - 0.77，P = 0.010）和持续使用者（HR 0.48，95% CI 0.25 - 0.90，P = 0.022）的IBD相关手术风险也低于未使用者。对于使用处方氨基葡萄糖的患者，较高的处方剂量与较低的相关手术风险相关（比值比[OR]0.15，95% CI 0.02 - 0.86，P = 0.034）。
作为一种安全的膳食补充剂，氨基葡萄糖的使用与较低的IBD相关手术风险相关，这可能是IBD管理中的一种有前景的策略。
